BPC-157 and TB-500 “Wolverine Stack”: Legal Status in 2026
The FDA’s new interim enforcement discretion policy means BPC-157 and TB-500 can now be compounded by state-licensed 503A pharmacies, but only for individual patients who have a prescription. The peptides are still unapproved drugs, remain on the World Anti-Doping Agency Prohibited List, and research-only vials sold online sit completely outside the policy.
BPC-157 and TB-500-often marketed together as the “Wolverine stack” for tissue repair-are not FDA-approved drugs, but as of October 28 2026 they may be legally compounded by a 503A pharmacy if you have a valid prescription. The new interim enforcement discretion policy lets compounders prepare these peptides when a licensed prescriber determines a patient needs them, provided strict quality, labeling, and safety-reporting conditions are met. The policy is temporary, does not bind state boards of pharmacy, and can be revoked if problems emerge.
- The FDA’s interim policy covers six peptides, including BPC-157 and TB-500, for patient-specific 503A compounding but does not list them as FDA-approved drugs.
- FDA staff reviewers found no human safety studies for TB-500, and found the BPC-157 human studies too small and too short.
- Both peptides remain prohibited for in-competition and out-of-competition use under the World Anti-Doping Agency rules (Tham et al., 2026).
- Research-use-only (RUO) vials sold online fall completely outside the policy and carry contamination and dosing risks (Moiz et al., 2026).
- Rx.com plans to offer prescription compounded versions of these peptides through U.S.-licensed providers and a licensed 503A pharmacy (coming soon).
What BPC-157 and TB-500 Are-A Quick Definition
BPC-157 is a 15-amino-acid fragment of body protection compound (a protein found in gastric juice), while TB-500 is a seven-amino-acid fragment of thymosin β-4. Preclinical models suggest BPC-157 may up-regulate growth-factor signaling and angiogenesis, and TB-500 may modulate actin binding to aid cell migration, both potentially supporting tissue repair (Rahman et al., 2026). When used together they are informally called the “Wolverine stack,” referencing the comic character’s rapid healing.
Neither peptide has an FDA-approved product. Legal access today runs through a valid prescription filled by a state-licensed 503A compounding pharmacy. Rx.com plans to offer prescription compounded BPC-157 and TB-500 through U.S.-licensed providers and a licensed 503A pharmacy (coming soon).
How the 2026 Interim Policy Changes Access
The policy gives FDA discretion not to enforce the usual rules against 503A pharmacies and physicians that compound BPC-157 or TB-500 for an identified patient with a prescription, as long as they meet its conditions on ingredient quality, manufacturing standards, labeling and safety reporting.
The policy followed a July 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting where members recommended access despite FDA staff objections. It is interim; FDA can revise or withdraw it if safety issues arise.
| Pathway | Is FDA-approved? | Requires prescription? | Quality oversight |
|---|---|---|---|
| 503A compounding under interim policy | No | Yes | State boards, plus the policy's conditions on quality, labeling and safety reporting |
| FDA new drug approval | Yes | Yes | Rigorous clinical trials and manufacturing inspections |
| Research-use-only vial online | No | No | None; unregulated |
Why the Policy Is Not the Same as FDA Approval
The interim policy does not put BPC-157 or TB-500 on the 503A bulks list and does not establish that they are safe or effective. Compounded peptides under the policy are still unapproved drugs.
States are free to adopt stricter rules. Some boards of pharmacy may decide not to allow compounding of these peptides at all, and the policy does not override such decisions. For a deeper dive, see how the bulks list works.
State-By-State Differences and RUO Loopholes
Because pharmacy practice is primarily regulated at the state level, your ability to fill a prescription for BPC-157 or TB-500 depends on where you live. A state board could interpret the policy narrowly or prohibit peptide compounding entirely.
RUO loophole: Many websites still sell unlabeled “for laboratory use only” vials. These products are not medicines, lack sterility and potency testing, and sit fully outside FDA’s interim policy. Contamination and dosing errors are common (Moiz et al., 2026). If you inject or ingest an RUO product, you assume all legal and medical risk.
⚠️ Check your state first
Before seeking a prescription, confirm that 503A pharmacies in your state may compound the peptide. Your prescriber or pharmacist can advise on local rules.
Anti-Doping Rules and Athlete Risks
Both BPC-157 and TB-500 are on the World Anti-Doping Agency (WADA) Prohibited List (Tham et al., 2026). Testing positive can lead to suspensions or loss of results, whether or not the peptide was prescribed.
Athletes should consult their sport’s governing body before starting any peptide therapy. Therapeutic Use Exemptions are rarely granted for unapproved drugs lacking human safety data.
| Regulatory body | Status of BPC-157 | Status of TB-500 |
|---|---|---|
| FDA | Unapproved; enforcement discretion for 503A compounding | Unapproved; enforcement discretion for 503A compounding |
| WADA | Prohibited | Prohibited |
| USADA | Follows WADA list | Follows WADA list |
What We Know (and Don’t) About Safety and Evidence
Human evidence is minimal. FDA staff reviewers found no human safety studies for TB-500 and found the BPC-157 human studies too small and too short. Animal studies suggest possible tendon and muscle healing effects (Biçer et al., 2026), but animal results often do not carry over to people.
Potential risks: Unregulated angiogenesis, off-target cell growth, infection from non-sterile vials, and unknown long-term effects top the list of concerns raised by physicians (Moiz et al., 2026). Until rigorous trials report dosing, pharmacokinetics, and adverse events, both peptides remain experimental.
For a broader overview of gray-market peptide risks, read our peptide regulations guide.
How to Verify a Legitimate Prescription Source
Look for these safeguards before filling a peptide prescription.
Is your peptide source legitimate?
Check the column that fits your situation:
✅ Likely Legitimate
- Written prescription from a U.S.-licensed prescriber
- Dispensed by a state-licensed 503A pharmacy
- Product has pharmacy label with patient name and lot number
- Provider explains that BPC-157 and TB-500 are experimental
- Access to pharmacist for questions and adverse-event reporting
🏥 Red Flags-See a Doctor First
- Website ships vials labelled “for research only, not for human use”
- No prescription or medical history required
- Claims of “FDA approved” or “legal in all 50 states”
- Promises to beat anti-doping tests
- No lot number, expiration date, or sterility info on the vial
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Sudden swelling or redness at the injection site: could indicate infection.
- Unexplained bleeding or bruising: possible coagulation changes.
- Severe headache or vision changes: may signal abnormal blood-vessel growth.
- Chest pain or shortness of breath: potential cardiovascular reaction.
- Rapid, unexplained weight gain: fluid retention can strain the heart.
- Lump, mass, or unusual growth: report any suspicious tissue changes promptly.
- Persistent abdominal pain or jaundice: could involve liver stress.
- Mood changes or depression: emerging psychiatric symptoms need quick evaluation.
Frequently Asked Questions
Scientific References
- Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg. 2026.
- Moiz A, O'Keefe EL, O'Keefe JH. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Mo Med. 2026.
- Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026.
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026.
Is the “Wolverine stack” legal for general fitness use?
With a valid prescription, a state-licensed 503A pharmacy can compound BPC-157 and TB-500 for an individual patient under the interim policy. Research vials bought online are outside the policy and risky.
Does the interim policy mean FDA endorses these peptides?
No. The policy only states FDA will not take enforcement action against qualifying compounders. It explicitly says the peptides are still unapproved drugs.
Will WADA grant a Therapeutic Use Exemption (TUE)?
It is unlikely. WADA rarely grants TUEs for unapproved substances lacking human data. Talk to your sport’s medical director before starting any peptide.
How can I tell if a product is “research use only”?
RUO vials usually lack your name, dose instructions, and pharmacy labeling. The bottle may say “not for human consumption” or arrive without a box insert.
Does combining BPC-157 with TB-500 enhance results?
No human study has tested the combination, so claims of additive benefits are speculative. Animal data are too limited to guide dosing or predict safety (Biçer et al., 2026).
What if the interim policy changes?
The policy is interim, and HHS may reconsider it if safety or quality problems emerge.
